Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 1

Baseline demographics and characteristics associated with intervention.

Characteristic	Total population (n = 187)	EVT group (n = 94)	Bypass group (n = 93)	value
Age (years)	75.1 ± 11.9	75.8 ± 13.4	74.4 ± 10.3	0.424
BMI	23.4 ± 4.4	24 ± 3.7	22.8 ± 5.0	0.079
SBP	137.1 ± 24.1	137.1 ± 24.1	137.1 ± 24.2	0.988
Gender (female)	52 (27.8)	26 (27.7)	26 (28.0)	0.964
Lesion site (left)	91 (48.7)	45 (47.9)	46 (49.5)	0.828
Baseline CAD	71 (38)	34 (36.2)	37 (39.8)	0.611
ESRD (regular dialysis)	66 (35.6)	36 (38.3)	30 (32.3)	0.388
DM	112 (59.9)	61 (64.9)	51 (54.8)	0.161
Hypertension	154 (82.4)	76 (80.9)	78 (83.9)	0.588
Hyperlipidemia	51 (27.3)	25 (26.6)	26 (28.0)	0.321
Baseline CVA	24 (12.8)	15 (16)	9 (9.7)	0.199
Smoking	75 (40.3)	35 (37.6)	40 (43.0)	0.455
Cellulitis on presentation	145 (77.5)	74 (78.7)	71 (76.3)	0.697
Atrial fibrillation	14 (7.5)	9 (9.6)	5 (5.4)	0.275
Baseline ABI	0.52 ± 0.13	0.51 ± 0.11	0.53 ± 0.16	0.473
Calcification	75 (43.6)	36 (42.4)	39 (44.8)	0.744
Retinopathy	28 (15)	18 (19.1)	10 (10.8)	0.108
Neuropathy	49 (26.2)	29 (30.9)	20 (21.5)	0.146
Rutherford classification				0.757
Stage III	17 (9.1)	10 (10.6)	7 (7.5)
Stage IV	41 (21.9)	20 (21.3)	21 (22.6)
Stage V plus VI	129 (69)	64 (68.1)	65 (66.9)
hsCRP (mg/L)	4.85 ± 5.23	4.45 ± 4.99	5.28 ± 5.49	0.297
HA1c (%)	7.51 ± 1.57	7.57 ± 1.57	7.43 ± 1.59	0.659
Concomitant medications
OHA alone	65 (37.8)	27 (31.8)	38 (43.7)	0.107
Insulin alone	55 (29.4)	30 (31.9)	25 (26.9)	0.450

ABI: ankle brachial index; BMI: body mass index; SBP: systolic blood pressure; CAD: coronary artery disease; CVA: cerebral vascular accident; DM: diabetes mellitus; ESRD: end-stage renal disease; EVT, endovascular therapy; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; OHA, oral hypoglycemic agent.